Нepatoprotective еffects of lithium ascorbate on a model of nonalcoholic fatty liver disease with iron overload

Lithium ascorbate is a lithium salt with normothymic and neuroprotective properties. In an experimental model of non-alcoholic fatty liver disease with multiorgan pathology caused by combined consumption of excessive amounts of saturated fats, carbohydrates and inorganic iron salt, the use of lithium ascorbate showed pronounced hepatoprotective effects. The introduction of lithium ascorbate reduced the level of ferritin and transferrin saturation, the content of serum iron, AST, ALT, serum creatinine, leukocytes and normalized the level of serum protein and the rate of glomerular filtration. Lithium ascorbate reduced the increased content of reticulocytes and platelets to control values, restored the levels of vitamins C, B₁₂ in the blood and reduced the number of Kupffer cells in the liver, which were overloaded with iron. The hepatoprotective effect of lithium ascorbate was confirmed histologically. The ability of the neuroprotector lithium ascorbate to reduce the level of hemosiderosis can be used in the treatment of patients with hepatic encephalopathy.

1. Torshin IY, Gromova OA, Ostrenko KS, et al. Lithium Ascorbate as a Promising Neuroprotector: Fundamental and Experimental Studies of an Organic Lithium Salt. Molecules. 2022 Mar 30;27(7):2253. doi: 10.3390/molecules27072253.

2. Torshin IYu, Sardaryan IS, Gromova OA, et al. Chemoreactome modeling the effects of anions of lithium salts ascorbate, nicotinate, hydroxybutyrate komenata and lithium carbonate. Farmakokinetika i farmakodinamika. 2016;(3):47-57. (In Russ.).

3. Nazarenko OA, Demidov VI, Gromova OA, et al. Comparative study of the neuroprotective activity of lithium compounds and their effect on the course of experimental alloxan diabetes mellitus in rats. Farmakokinetika i farmakodinamika. 2020;(3):40-47. (In Russ.). doi: 10.37489/2587-7836-2020-3-40-47.

4. Bogacheva TE, Kalacheva AG, Gromova OA, et al. Study of the effectiveness of the drug Laennek in case of liver damage by palm oil in rats. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2023;(4):23–31. (In Russ.). doi: 10.37489/2587-7836-2023-4-23-31.

5. Zhuo Z, Fang S, Hu Q, et al. Digital gene expression profiling analysis of duodenum transcriptomes in SD rats administered ferrous sulfate or ferrous glycine chelate by gavage. Sci Rep. 2016 Nov 30;6:37923. doi: 10.1038/srep37923.

6. Luo G, Xiang L, Xiao L. Acetyl-CoA Deficiency Is Involved in the Regulation of Iron Overload on Lipid Metabolism in Apolipoprotein E Knockout Mice. Molecules. 2022 Aug 4;27(15):4966. doi: 10.3390/molecules27154966.

7. Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship. Int J Obes (Lond). 2023 Jul;47(7):554-563. doi: 10.1038/s41366-023-01299-0.

8. Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018 May;68(5):1063-1075. doi: 10.1016/j.jhep.2018.01.019.

9. Ma J, Sloan M, Fox CS, et al. Sugar-sweetened beverage consumption is associated with abdominal fat partitioning in healthy adults. J Nutr. 2014 Aug;144(8):1283-90. doi: 10.3945/jn.113.188599.

10. DiStefano JK. Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Cell Mol Life Sci. 2020 Jun;77(11):2079-2090. doi: 10.1007/s00018-019-03390-0.

11. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013 Jun;57(6):2525-31. doi: 10.1002/hep.26299.

12. Kanerva N, Sandboge S, Kaartinen NE, et al. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014 Oct;100(4):1133-8. doi: 10.3945/ajcn.114.086074.

13. Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015 Aug;63(2):462-9. doi: 10.1016/j.jhep.2015.03.032.

14. Sheptulina AF, Golubeva YuA, Drapkina OM. Fructose consumption as a risk factor for metabolic syndrome and nonalcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2023;12(1):85 92. (In Russ.). doi: 10.17116/dokgastro20231201185.